Clinical Cancer Research, Vol 3, Issue 4 545-552, Copyright © 1997 by American Association for Cancer Research

ARTICLES

Detection of in vivo P-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi

CC Chen, B Meadows, J Regis, G Kalafsky, T Fojo, JA Carrasquillo and SE Bates
Department of Nuclear Medicine, Warren G. Magnuson Clinical Center, Division of Clinical Sciences, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA.

Tc-99m sestamibi is a substrate of P-glycoprotein (Pgp) that has been proposed for use as a functional imaging agent for the multidrug resistance-1 phenotype. In vitro, retention of sestamibi by cells that overexpress Pgp can be modified by the presence of Pgp antagonists. In a Phase I trial of the Pgp reversal agent PSC 833, we show that the effects of this reversal agent can also be demonstrated in patients. Nine patients with metastatic renal carcinoma were studied three times: at baseline, approximately 1 day after vinblastine infusion, and while on PSC 833. One patient with metastatic adrenocortical cancer was also studied. Time activity curves and areas under the curve (AUCs) were obtained for tumor, liver, lung, and myocardium, and organ:heart AUC ratios were generated. With PSC 833, tumor visualization was enhanced, and statistically significant increases were found in AUC ratios for tumor and liver compared to baseline. For the liver, significant differences were also found between the vinblastine versus PSC 833 scans but not between the baseline versus vinblastine scans. This study demonstrates that sestamibi retention by tumor and liver is altered in the presence of the reversal agent PSC 833, presumably reflecting inhibition of Pgp. Thus, sestamibi may be useful in vivo as a means of monitoring the effects of this and other reversal agents on various tumors and normal tissues that express Pgp.

This article has been cited by other articles:

				C. Bolzati, M. Cavazza-Ceccato, S. Agostini, S. Tokunaga, D. Casara, and G. Bandoli Subcellular Distribution and Metabolism Studies of the Potential Myocardial Imaging Agent [99mTc(N)(DBODC)(PNP5)]+ J. Nucl. Med., August 1, 2008; 49(8): 1336 - 1344. [Abstract] [Full Text] [PDF]

				M. Michael, M. Thompson, R. J. Hicks, P. L. Mitchell, A. Ellis, A. D. Milner, J. Di Iulio, A. M. Scott, V. Gurtler, J. M. Hoskins, et al. Relationship of Hepatic Functional Imaging to Irinotecan Pharmacokinetics and Genetic Parameters of Drug Elimination J. Clin. Oncol., September 10, 2006; 24(26): 4228 - 4235. [Abstract] [Full Text] [PDF]

				D. L. Kroetz Role for Drug Transporters Beyond Tumor Resistance: Hepatic Functional Imaging and Genotyping of Multidrug Resistance Transporters for the Prediction of Irinotecan Toxicity J. Clin. Oncol., September 10, 2006; 24(26): 4225 - 4227. [Full Text] [PDF]

				V. S. Donnenberg and A. D. Donnenberg Multiple Drug Resistance in Cancer Revisited: The Cancer Stem Cell Hypothesis J. Clin. Pharmacol., August 1, 2005; 45(8): 872 - 877. [Abstract] [Full Text] [PDF]

				A. Pichler, N. Zelcer, J. L. Prior, A. J. Kuil, and D. Piwnica-Worms In vivo RNA Interference-Mediated Ablation of MDR1 P-Glycoprotein Clin. Cancer Res., June 15, 2005; 11(12): 4487 - 4494. [Abstract] [Full Text] [PDF]

				V. Sharma, J. L. Prior, M. G. Belinsky, G. D. Kruh, and D. Piwnica-Worms Characterization of a 67Ga/68Ga Radiopharmaceutical for SPECT and PET of MDR1 P-Glycoprotein Transport Activity In Vivo: Validation in Multidrug-Resistant Tumors and at the Blood-Brain Barrier J. Nucl. Med., February 1, 2005; 46(2): 354 - 364. [Abstract] [Full Text] [PDF]

				K. Kawata, M. Kanai, T. Sasada, S. Iwata, N. Yamamoto, and A. Takabayashi Usefulness of 99mTc-Sestamibi Scintigraphy in Suggesting the Therapeutic Effect of Chemotherapy against Gastric Cancer Clin. Cancer Res., June 1, 2004; 10(11): 3788 - 3793. [Abstract] [Full Text] [PDF]

				G J R Cook Oncological molecular imaging: nuclear medicine techniques Br. J. Radiol., December 1, 2003; 76(suppl_2): S152 - S158. [Full Text] [PDF]

				G. D. Leonard, T. Fojo, and S. E. Bates The Role of ABC Transporters in Clinical Practice Oncologist, October 1, 2003; 8(5): 411 - 424. [Abstract] [Full Text] [PDF]

				K. A. Kurdziel, D. O. Kiesewetter, R. E. Carson, W. C. Eckelman, and P. Herscovitch Biodistribution, Radiation Dose Estimates, and In Vivo Pgp Modulation Studies of 18F-Paclitaxel in Nonhuman Primates J. Nucl. Med., August 1, 2003; 44(8): 1330 - 1339. [Abstract] [Full Text] [PDF]

				M. Agrawal, J. Abraham, F. M. Balis, M. Edgerly, W. D. Stein, S. Bates, T. Fojo, and C. C. Chen Increased 99mTc-Sestamibi Accumulation in Normal Liver and Drug-resistant Tumors after the Administration of the Glycoprotein Inhibitor, XR9576 Clin. Cancer Res., February 1, 2003; 9(2): 650 - 656. [Abstract] [Full Text] [PDF]

				H. Palmedo What Can We Expect from MDR Breast Cancer Imaging with Sestamibi? J. Nucl. Med., April 1, 2002; 43(4): 526 - 530. [Full Text] [PDF]

				R. Gorlick, A. C. Liao, C. Antonescu, A. G. Huvos, J. H. Healey, R. Sowers, M. Daras, E. Calleja, L. H. Wexler, D. Panicek, et al. Lack of Correlation of Functional Scintigraphy with 99mTechnetium-Methoxyisobutylisonitrile with Histological Necrosis following Induction Chemotherapy or Measures of P-Glycoprotein Expression in High-Grade Osteosarcoma Clin. Cancer Res., October 1, 2001; 7(10): 3065 - 3070. [Abstract] [Full Text] [PDF]

				R. A. Peck, J. Hewett, M. W. Harding, Y.-M. Wang, P. R. Chaturvedi, A. Bhatnagar, H. Ziessman, F. Atkins, and M. J. Hawkins Phase I and Pharmacokinetic Study of the Novel MDR1 and MRP1 Inhibitor Biricodar Administered Alone and in Combination With Doxorubicin J. Clin. Oncol., June 15, 2001; 19(12): 3130 - 3141. [Abstract] [Full Text] [PDF]